Keywords
Menopause
Therapeutics
Neurokinin B
Neurokinin-1 receptor antagonists
How to Cite
Abstract
Objective: To evaluate the efficacy and safety of fezolinetant in the treatment of vasomotor symptoms in menopausal women. Materials and methods: A systematic review of the literature was conducted in various electronic databases (Embase, Google Scholar, Pubmed, SciELO, among others) using standardized, open-source search terms, with no language restrictions, between 1980 and 2025. Publications were screened according to inclusion and exclusion criteria. Results: Fifty-eight studies were included, of which five were systematic reviews and seven were meta-analyses. Fezolinetant was shown to be effective and safe in reducing the frequency and severity of vasomotor symptoms (VMS) compared with placebo in postmenopausal women. A 60% to 70% reduction in VMS intensity was observed across different levels. Serious adverse events associated with treatment were rare (2%, 1%, and 0% in women receiving fezolinetant 30 mg, fezolinetant 45 mg, and placebo, respectively). Conclusions: Fezolinetant effectively reduces VMS in postmenopausal women. It also improves quality of life and sleep disturbances, with an adequate safety profile. There is a potential risk of elevated liver enzymes, which require regular monitoring of liver function.
1. Sorpreso IC, Soares Júnior JM, Fonseca AM, Baracat EC. Female aging. Rev Assoc Med Bras (1992). 2015 Nov-Dec;61(6):553-6. https://doi.org/10.1590/1806-9282.61.06.553.
2. Espitia De La Hoz FJ. Prevalencia y caracterización de los síntomas de la menopausia en mujeres climatéricas del Eje Cafetero (Colombia), 2018-2020. Univ Med. 2022 Jul-Sep;63(3). https://doi.org/10.11144/Javeriana.umed63-3.smmc
3. Santoro N, Roeca C, Peters BA, Neal-Perry G. The menopause transition: signs, symptoms, and management options. J Clin Endocrinol Metab. 2021 Jan 1;106(1):1-15. https://doi.org/10.1210/clinem/dgaa764
4. Espitia De La Hoz FJ. Prevalencia y severidad de los síntomas de la menopausia en mujeres mayores de 60 años. Rev Colomb Endocrinol Diabet Metab. 2024;11(1):e853. https://doi.org/10.53853/encr.11.1.853
5. Davis SR, Pinkerton J, Santoro N, Simoncini T. Menopause-Biology, consequences, supportive care, and therapeutic options. Cell. 2023 Sep 14;186(19):4038-58. https://doi.org/10.1016/j.cell.2023.08.016.
6. Castelo-Branco C, Blümel JE, Chedraui P, Calle A, Bocanera R, Depiano E, et al. Age at menopause in Latin America. Menopause. 2006 Jul-Aug;13(4):706-12. https://doi.org/10.1097/01.gme.0000227338.73738.2d
7. Monterrosa Castro Á, Salguedo Madrid M, Carrascal JM. Correlación entre síntomas menopáusicos y percepción de estrés en mujeres del caribe colombiano. Medicina (Bogotá). 2016; 38(1):25-38.
8. Hill K. The demography of menopause. Maturitas. 1996 Mar;23(2):113-27. https://doi.org/10.1016/0378-5122(95)00968-x.
9. Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause. 2014 Sep;21(9):924-32. https://doi.org/10.1097/GME.0000000000000196
10. Palacios S, Henderson VW, Siseles N, Tan D, Villaseca P. Age of menopause and impact of climacteric symptoms by geographical region. Climacteric. 2010 Oct;13(5):419-28. https://doi.org/10.3109/13697137.2010.507886
11. Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, Hess R, Joffe H, Kravitz HM, Tepper PG, Thurston RC; Study of women's health across the nation: duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015 Apr;175(4):531-9. https://doi.org/10.1001/jamainternmed.2014.8063
12. Worsley R, Bell RJ, Gartoulla P, Robinson PJ, Davis SR. Moderate-severe vasomotor symptoms are associated with moderate-severe depressive symptoms. J Womens Health (Larchmt). 2017 Jul;26(7):712-718. https://doi.org/10.1089/jwh.2016.6142
13. Whiteley J, Wagner JS, Bushmakin A, Kopenhafer L, Dibonaventura M, Racketa J. Impact of the severity of vasomotor symptoms on health status, resource use, and productivity. Menopause. 2013 May;20(5):518-24. https://doi.org/10.1097/GME.0b013e31827d38a5
14.Williams RE, Levine KB, Kalilani L, Lewis J, Clark RV. Menopause-specific questionnaire assessment in US population-based study shows negative impact on health-related quality of life. Maturitas. 2009 Feb 20;62(2):153-9. https://doi.org/10.1016/j.maturitas.2008.12.006
15. Ameye L, Antoine C, Paesmans M, de Azambuja E, Rozenberg S. Menopausal hormone therapy use in 17 European countries during the last decade. Maturitas. 2014 Nov;79(3):287-91. https://doi.org/10.1016/j.maturitas.2014.07.002
16. Yuksel N, Todorova L, Scrine L, Rea C, Bouchard C. Prevalence and impact of vasomotor symptoms due to menopause among women in Canada: a subgroup analysis from an international cross-sectional survey of Women with Vasomotor Symptoms Associated with Menopause (WARM Study). Menopause. 2025 Jan 1;32(1):38-44. https://doi.org/10.1097/GME.0000000000002451
17. DePree B, Houghton K, DiBenedetti DB, Shiozawa A, King DD, Kim J, Mancuso S. Practice patterns and perspectives regarding treatment for symptoms of menopause: qualitative interviews with US health care providers. Menopause. 2023 Feb 1;30(2):128-135. https://doi.org/10.1097/GME.0000000000002096
18. Cucinella L, Tedeschi S, Memoli S, Cassani C, Martini E, Nappi RE. Pharmacokinetic evaluation of fezolinetant for the treatment of vasomotor symptoms caused by menopause. Expert Opin Drug Metab Toxicol. 2025 Jan-Feb;21(2):105-13. https://doi.org/10.1080/17425255.2024.2416046
19. Pertynska-Marczewska M, Pertynski T. Non-hormonal pharmacological interventions for managing vasomotor symptoms-how can we help: 2024 landscape. Eur J Obstet Gynecol Reprod Biol. 2024 Nov;302:141-8. https://doi.org/10.1016/j.ejogrb.2024.09.013
20. Gentry-Maharaj A, Karpinskyj C, Glazer C, Burnell M, Ryan A, Fraser L, Lanceley A, Jacobs I, Hunter MS, Menon U. Use and perceived efficacy of complementary and alternative medicines after discontinuation of hormone therapy: a nested United Kingdom Collaborative Trial of Ovarian Cancer Screening cohort study. Menopause. 2015 Apr;22(4):384-90. https://doi.org/10.1097/GME.0000000000000330
21. Posadzki P, Lee MS, Moon TW, Choi TY, Park TY, Ernst E. Prevalence of complementary and alternative medicine (CAM) use by menopausal women: a systematic review of surveys. Maturitas. 2013 May;75(1):34-43. https://doi.org/10.1016/j.maturitas.2013.02.005
22. “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022 Jul 1;29(7):767-794. https://doi.org/10.1097/GME.0000000000002028
23. Sundell M, Brynhildsen J, Spetz Holm AC, Fredrikson M, Hoffmann M. Trends in the incidence, prevalence and sales volume of menopausal hormone therapy in Sweden from 2000 to 2021. Maturitas. 2023 Sep;175:107787. https://doi.org/10.1016/j.maturitas.2023.107787
24. Heinig M, Braitmaier M, Haug U. Prescribing of menopausal hormone therapy in Germany: Current status and changes between 2004 and 2016. Pharmacoepidemiol Drug Saf. 2021 Apr;30(4):462-471. https://doi.org/10.1002/pds.5186. Epub 2021 Jan 11
25. Espitia De La Hoz FJ. Terapia hormonal en la menopausia vía transdérmica: un asunto de eficacia y seguridad. Gac Med Bol. 2024;47(1):72-85. https://doi.org/10.47993/gmb.v47i1.606
26. Madsen TE, Sobel T, Negash S, Shrout Allen T, Stefanick ML, Manson JE, Allison M. A Review of Hormone and Non-Hormonal Therapy Options for the Treatment of Menopause. Int J Womens Health. 2023 May 25;15:825-36. https://doi.org/10.2147/IJWH.S379808
27. Sahni S, Lobo-Romero A, Smith T. Contemporary Non-hormonal Therapies for the Management of Vasomotor Symptoms Associated with Menopause: A Literature Review. touchREV Endocrinol. 2021 Nov;17(2):133-7. https://doi.org/10.17925/EE.2021.17.2.133
28. Raccah-Tebeka B, Boutet G, Plu-Bureau G. Alternatives non hormonales de prise en charge des bouffées vasomotrices post-ménopausiques. RPC Les femmes ménopausées du CNGOF et du GEMVi [Non-hormonal alternatives for the management of menopausal hot flushes. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines]. Gynecol Obstet Fertil Senol. 2021 May;49(5):373-93. French. https://doi.org/10.1016/j.gofs.2021.03.020
29. Depypere H, Lademacher C, Siddiqui E, Fraser GL. Fezolinetant in the treatment of vasomotor symptoms associated with menopause. Expert Opin Investig Drugs. 2021 Jul;30(7):681-94. https://doi.org/10.1080/13543784.2021.1893305
30. Johnson KA, Martin N, Nappi RE, Neal-Perry G, Shapiro M, Stute P, Thurston RC, Wolfman W, English M, Franklin C, Lee M, Santoro N. Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: a phase 3 RCT. J Clin Endocrinol Metab. 2023 Jul 14;108(8):1981-97. https://doi.org/10.1210/clinem/dgad058
31. Neal-Perry G, Cano A, Lederman S, Nappi RE, Santoro N, Wolfman W, et al. Safety of fezolinetant for vasomotor symptoms associated with menopause: a randomized controlled trial. Obstet Gynecol. 2023 Apr 1;141(4):737-47. https://doi.org/10.1097/AOG.0000000000005114
32. U.S. Food and Drug Administration. FDA approves novel drug to treat moderate to severe hot flashes caused by menopause [internet]. Silver Spring (MD): FDA; 2023. Disponible en: https://www.fda.gov/news-events/press-announcements/fda-approves-novel-drug-treat-moderate-severe-hot-flashes-caused-menopause
33. Morga A, Ajmera M, Gao E, Patterson-Lomba O, Zhao A, Mancuso S, et al. Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause. Menopause. 2024 Jan 1;31(1):68-76. https://doi.org/10.1097/GME.0000000000002281
34. Ministerio de Salud y Protección Social. Resolución 8430 del 4 de octubre de 1993, por la cual se establecen normas científicas, técnicas y administrativas para la investigación en salud [internet]. Disponible en: https://normograma.invima.gov.co/compilacion/docs/resolucion_minsalud_r8430_93.htm
35. Elnaga AAA, Alsaied MA, Elettreby AM, Ramadan A. Effectiveness and safety of fezolinetant in alleviating vasomotor symptoms linked to menopause: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2024 Jun;297:142-52. https://doi.org/10.1016/j.ejogrb.2024.04.017
36. Akhtar SMM, Ali A, Khan MS, Khan V, Fareed A, Saleem SZ, et al. Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Int J Gynaecol Obstet. 2024 Sep;166(3):969-83. https://doi.org/10.1002/ijgo.15467
37. Shapiro C M M, Wu X, Wang X, Miyazaki K, Morga A, Nappi RE, et al. Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy. Maturitas. 2025 Feb;193:108159. https://doi.org/10.1016/j.maturitas.2024.108159
38. Ali S, Ilyas MA. Fezolinetant: A novel NK3R antagonist for treating postmenopausal vasomotor symptoms. J Pak Med Assoc. 2024 Aug;74(8):1582. https://doi.org/10.47391/JPMA.20096
39. Lederman S, Ottery FD, Cano A, Santoro N, Shapiro M, Stute P, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023 Apr 1;401(10382):1091-102. https://doi.org/10.1016/S0140-6736(23)00085-5
40. Depypere H, Timmerman D, Donders G, Sieprath P, Ramael S, Combalbert J, et al. Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial. J Clin Endocrinol Metab. 2019 Dec 1;104(12):5893-905. https://doi.org/10.1210/jc.2019-00677
41. Schaudig K, Wang X, Bouchard C, Hirschberg AL, Cano A, Shapiro C M M, et al. Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial. BMJ. 2024 Nov 18;387:e079525. https://doi.org/10.1136/bmj-2024-079525
42. Santoro N, Neal-Perry G, Stute P, Blogg M, Mancuso S, Morga A, et al. Fezolinetant effect on vasomotor symptoms due to menopause in women unsuitable for hormone therapy. Curr Med Res Opin. 2025 Feb;41(2):375-84. https://doi.org/10.1080/03007995.2025.2470752
43. Cucinella L, Cassani C, Tedeschi S, Memoli S, Martini E, Nappi RE. A profile of safety and efficacy of fezolinetant for the treatment of menopausal vasomotor symptoms. Expert Rev Clin Pharmacol. 2025 May;18(5):247-58. https://doi.org/10.1080/17512433.2025.2495951
44. Onge ES, Phillips B, Miller L. Fezolinetant: a new nonhormonal treatment for vasomotor symptoms. J Pharm Technol. 2023 Dec;39(6):291-7. https://doi.org/10.1177/87551225231198700
45. Roberts MZ, Andrus MR. Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause. Expert Opin Pharmacother. 2024 Jun;25(9):1131-6. https://doi.org/10.1080/14656566.2024.2375039
46. Yu Q, Ming F, Ma J, Cai Y, Wang L, Ren M, et al. Long-term safety of fezolinetant in Chinese women with vasomotor symptoms associated with menopause: the phase 3 open-label MOONLIGHT 3 clinical trial. J Int Med Res. 2024 May;52(5):3000605241246624. https://doi.org/10.1177/03000605241246624
47. Chávez MP, Pasqualotto E, Ferreira ROM, Hohl A, de Moraes FCA, Schmidt PHS, et al. Fezolinetant for the treatment of vasomotor symptoms associated with menopause: a meta-analysis. Climacteric. 2024 Jun;27(3):245-54. https://doi.org/10.1080/13697137.2024.2334083
48. Bonga KN, Mishra A, Maiti R, Padhy BM, Meher BR, Srinivasan A. Efficacy and safety of fezolinetant for the treatment of menopause-associated vasomotor symptoms: a meta-analysis. Obstet Gynecol. 2024 Mar 1;143(3):393-402. https://doi.org/10.1097/AOG.0000000000005508
49. Elhusein AM, Fadlalmola HA, Abedelwahed HH, Elshaikh AA, Banaga AE, Alrahman MHF, et al. Menopausal symptom management: fezolinetant's varied doses provide effective relief for vasomotor symptoms in women. A meta-analysis of 3291 participants. Afr J Reprod Health. 2024 Mar 31;28(3):99-113. https://doi.org/10.29063/ajrh2024/v28i3.11
50. AlBarakat MM, Feras AlSamhori J, Abdelaziz A, Elrosasy A, Elzeftawy MA, Ahmed Youssef R, et al. Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: a comprehensive systematic review and meta-analysis of randomized controlled trials. Proc (Bayl Univ Med Cent). 2025 Jun 17;38(4):535-46. https://doi.org/10.1080/08998280.2025.2491894
51. Kagan R, Cano A, Nappi RE, English ML, Mancuso S, Wu X, et al. Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies. Adv Ther. 2025 Feb;42(2):1147-64. https://doi.org/10.1007/s12325-024-03073-8
52. Fezolinetant (Veozah) for menopausal vasomotor symptoms. Med Lett Drugs Ther. 2023 Jun 26;65(1679):97-9. https://doi.org/10.58347/tml.2023.1679a
53. Lee A. Fezolinetant: first approval. Drugs. 2023 Aug;83(12):1137-41. https://doi.org/10.1007/s40265-023-01917-1
54. Nappi RE, Johnson KA, Stute P, Blogg M, English M, Morga A, et al. Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2). Menopause. 2024 Jun 1;31(6):512-21. https://doi.org/10.1097/GME.0000000000002354
55. Shapiro C M M, Cano A, Nappi RE, Santoro N, English ML, Mancuso S, et al. Effect of fezolinetant on sleep disturbance and impairment during treatment of vasomotor symptoms due to menopause. Maturitas. 2024 Aug;186:107999. https://doi.org/10.1016/j.maturitas.2024.107999
56. Takamatsu K, Miki T, Miyazaki K, Hashimoto A, He W, Wang X. Phase II study of fezolinetant for treatment of vasomotor symptoms associated with menopause in Japan. Climacteric. 2024 Aug;27(4):389-97. https://doi.org/10.1080/13697137.2024.2356854
57. Ruan X, Bai W, Ren M, Kim T, Lee JY, Chuang FC, et al. Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I). J Int Med Res. 2024 May;52(5):3000605241247684. https://doi.org/10.1177/03000605241247684
58. Cieri-Hutcherson NE, Marji EK, Hutcherson TC. Systematic review of neurokinin-3 receptor antagonists for the management of vasomotor symptoms of menopause. Menopause. 2024 Apr 1;31(4):342-54. https://doi.org/10.1097/GME.0000000000002328
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Franklin José Espitia-De La Hoz